Institute of Nephrology-Department of Medicine, University G. d'Annunzio, Chieti-Pescara, Italy.
PLoS One. 2012;7(1):e30682. doi: 10.1371/journal.pone.0030682. Epub 2012 Jan 25.
Calcimimetics, such as R-568, are thought to activate G protein-linked Ca(2+)-sensing receptor (CaSR) by allosterically increasing the affinity of the receptor for Ca(2+) allowing for efficient control of uremic hyperparathyroidism. Several recent studies suggest they possess additional vascular actions. Although it has been postulated that calcimimetics may have a direct effect on CaSR in the blood vessels, further studies are needed to elucidate their vascular CaSR-dependent versus CaSR-independent effects.
METHODOLOGY/PRINCIPAL FINDINGS: Focusing on human umbilical vein endothelial cells (HUVECs), we studied the CaSR expression and distribution by Immunofluorescence and Western Blot analysis. CaSR function was evaluated by measuring the potential effect of calcimimetic R-568 and its enantiomer S-568 upon the modulation of intracellular Ca(2+) levels (using a single cell approach and FURA-2AM), in the presence or absence of Calhex-231, a negative modulator of CaSR. To address their potential vascular functions, we also evaluated R- and S-568-stimulated enzymatic release of Nitric Oxide (NO) by DAF-2DA, by Nitric Oxide Synthase (NOS) radiometric assay (both in HUVECs and in Human Aortic Endothelial Cells) and by measuring eNOS-ser1177 phosphorylation levels (Immunoblotting). We show that, although the CaSR protein was expressed in HUVECs, it was mainly distributed in cytoplasm while the functional CaSR dimers, usually localized on the plasma membrane, were absent. In addition, regardless of the presence or absence of Calhex-231, both R- and S-568 significantly increased intracellular Ca(2+) levels by mobilization of Ca(2+) from intracellular stores, which in turn augmented NO release by a time- and Ca(2+)-dependent increase in eNOS-ser1177 phosphorylation levels.
CONCLUSIONS/SIGNIFICANCE: Taken together, these data indicate that in human endothelium there is no stereoselectivity in the responses to calcimimetics and that CaSR is probably not involved in the action of R- and S-568. This suggests an additional mechanism in support of the CaSR-independent role of calcimimetics as vasculotrope agents.
拟钙剂,如 R-568,被认为通过变构增加受体对 Ca(2+)的亲和力来激活 G 蛋白偶联的钙敏感受体 (CaSR),从而有效地控制尿毒症甲状旁腺功能亢进。最近的几项研究表明,它们具有额外的血管作用。虽然有人假设拟钙剂可能对血管中的 CaSR 有直接影响,但需要进一步研究来阐明它们的血管 CaSR 依赖性和非依赖性作用。
方法/主要发现:我们专注于人脐静脉内皮细胞 (HUVEC),通过免疫荧光和 Western Blot 分析研究 CaSR 的表达和分布。通过测量 CaSR 功能调节剂 Calhex-231 存在或不存在时,拟钙剂 R-568 及其对映体 S-568 对细胞内 Ca(2+)水平的调节作用(采用单细胞方法和 FURA-2AM),评估 CaSR 功能。为了研究它们的潜在血管功能,我们还评估了 R-和 S-568 刺激的一氧化氮 (NO) 酶释放,通过 DAF-2DA、通过一氧化氮合酶放射性测定(在 HUVEC 和人主动脉内皮细胞中)和通过测量 eNOS-ser1177 磷酸化水平(免疫印迹)。我们表明,尽管 HUVEC 中表达了 CaSR 蛋白,但它主要分布在细胞质中,而通常位于质膜上的功能性 CaSR 二聚体则不存在。此外,无论 Calhex-231 的存在与否,R-和 S-568 均通过从细胞内储存中动员 Ca(2+)显著增加细胞内 Ca(2+)水平,从而通过时间和 Ca(2+)依赖性增加 eNOS-ser1177 磷酸化水平来增加 NO 释放。
结论/意义:综上所述,这些数据表明,在人内皮细胞中,对拟钙剂的反应没有立体选择性,并且 CaSR 可能不参与 R-和 S-568 的作用。这表明存在一种额外的机制,支持拟钙剂作为血管作用剂的 CaSR 非依赖性作用。